Cargando…

Natural killer/T-cell lymphoma-associated hemophagocytic syndrome: A case report

Natural killer (NK)/T-cell lymphoma-associated hemophagocytic syndrome (HPS) is a rare and fatal disease with no optimal treatment. The present study reports the clinical features, diagnosis and treatment process of three patients with relapsed NK/T-cell lymphoma-associated HPS. All of the patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	HAN, LIJUAN, ZHANG, MINGZHI, LI, LING, ZHANG, LEI, WU, JINGJING, LI, XIN, WANG, XINHUA, YOUNG, KEN. H., FU, XIAORUI, MA, WANG, SUN, ZHENCHANG, ZHANG, XUDONG, CHANG, YU, QIAO, ZHI
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2014
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4081409/ https://www.ncbi.nlm.nih.gov/pubmed/25013513 http://dx.doi.org/10.3892/ol.2014.2202

Ejemplares similares

MicroRNA-155 is a potential molecular marker of natural killer/T-cell lymphoma
por: Zhang, Xudong, et al.
Publicado: (2016)

Gut microbiota as non-invasive diagnostic and prognostic biomarkers for natural killer/T-cell lymphoma
por: Shi, Zhuangzhuang, et al.
Publicado: (2023)

DDGP vs. SMILE in Relapsed/Refractory Extranodal Natural Killer/T‐cell Lymphoma, Nasal Type: A Retrospective Study of 54 Patients
por: Wang, Xin, et al.
Publicado: (2020)

Recurrent GNAQ mutation encoding T96S in natural killer/T cell lymphoma
por: Li, Zhaoming, et al.
Publicado: (2019)

Effective Treatment with PD-1 Antibody, Chidamide, Etoposide, and Thalidomide (PCET) for Relapsed/Refractory Natural Killer/T-Cell Lymphoma: A Report of Three Cases
por: Du, Lijun, et al.
Publicado: (2020)

Utility of baseline, interim and end-of-treatment (18)F-FDG PET/CT in extranodal natural killer/T-cell lymphoma patients treated with L-asparaginase/pegaspargase
por: Chang, Yu, et al.
Publicado: (2017)

Conserved cell populations in doxorubicin-resistant human nasal natural killer/T cell lymphoma cell line: super multidrug resistant cells?
por: Zhang, Xudong, et al.
Publicado: (2018)

Characteristics and Clinical Implications of the Nasal Microbiota in Extranodal NK/T-Cell Lymphoma, Nasal Type
por: Shi, Zhuangzhuang, et al.
Publicado: (2021)

Analyses and treatment of simultaneous bi-lineage malignancies of myeloid leukemia and lymphoma: Two case reports and a literature review
por: Fu, Xiaorui, et al.
Publicado: (2018)

Efficacy and safety of cisplatin, dexamethasone, gemcitabine and pegaspargase (DDGP) regimen in newly diagnosed, advanced-stage extranodal natural killer/T-cell lymphoma: interim analysis of a phase 4 study NCT01501149
por: Zhang, Lei, et al.
Publicado: (2016)

Phosphatase and tensin homolog (PTEN) is down-regulated in human NK/T-cell lymphoma and corrects with clinical outcomes
por: Fu, Xiaorui, et al.
Publicado: (2017)

Prognostic analysis of CD5 expression in double-hit diffuse large B-cell lymphoma and effectiveness comparison in patients treated with dose-adjusted EPOCH plus rituximab/R-CHOP regimens
por: Zhang, Fangwen, et al.
Publicado: (2019)

Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma
por: Li, Xin, et al.
Publicado: (2018)

Human immunodeficiency virus-negative plasmablastic lymphoma: A case report and literature review
por: Lin, Li, et al.
Publicado: (2017)

Baseline Total Metabolic Tumor Volume and Total Lesion Glycolysis Measured on (18)F-FDG PET-CT Predict Outcomes in T-Cell Lymphoblastic Lymphoma
por: Feng, Xiaoyan, et al.
Publicado: (2021)

B7-CD28 gene family expression is associated with prognostic and immunological characteristics of diffuse large B-cell lymphoma
por: Wang, Gangjian, et al.
Publicado: (2019)

An open label, single-armed, exploratory study of apatinib (a novel VEGFR-2 tyrosine kinase inhibitor) in patients with relapsed or refractory non-Hodgkin lymphoma
por: Li, Ling, et al.
Publicado: (2018)

T-cell dysfunction in natural killer/T-cell lymphoma
por: Feng, Xiaoyan, et al.
Publicado: (2023)

Apatinib in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: A Phase II, Open-Label, Single-Arm, Prospective Study
por: Ma, Xinran, et al.
Publicado: (2020)

Fotemustine, teniposide and dexamethasone versus high-dose methotrexate plus cytarabine in newly diagnosed primary CNS lymphoma: a randomised phase 2 trial
por: Wu, Jingjing, et al.
Publicado: (2018)

Role of programmed death ligands in effective T-cell interactions in extranodal natural killer/T-cell lymphoma
por: HAN, LIJUAN, et al.
Publicado: (2014)

AEG-1 is involved in hypoxia-induced autophagy and decreases chemosensitivity in T-cell lymphoma
por: Yan, Jiaqin, et al.
Publicado: (2018)

Gelsolin regulates proliferation, apoptosis and invasion in natural killer/T-cell lymphoma cells
por: Guo, Yanwei, et al.
Publicado: (2017)

Outcomes of GDPT (gemcitabine, cisplatin, prednisone, thalidomide) versus CHOP in newly diagnosed peripheral T-cell lymphoma patients
por: Sun, Yuanyuan, et al.
Publicado: (2020)

Decitabine combined with RDHAP regimen in relapsed/refractory diffuse large B cell lymphoma
por: Kong, Xiaoshuang, et al.
Publicado: (2023)

Ibrutinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Retrospective Study
por: Ren, Liangliang, et al.
Publicado: (2021)

Efficacy of dose-adjusted EPOCH plus rituximab/R-CHOP regimens and the prognosis analysis in patients with MYC, BCL2/BCL6 gene copy number gain lymphoma and double-hit lymphoma: results from a single institution retrospective clinical study
por: Ma, Qianwen, et al.
Publicado: (2019)

Clinical features and prognostic factors of primary bone marrow lymphoma
por: Wang, Gangjian, et al.
Publicado: (2019)

Non-coding RNAs in Natural Killer/T-Cell Lymphoma
por: Mei, Mei, et al.
Publicado: (2019)

Updating targets for natural killer/T-cell lymphoma immunotherapy
por: Xue, Weili, et al.
Publicado: (2021)

Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis
por: Wei, Liqiang, et al.
Publicado: (2020)

Combination of Decitabine and a Modified Regimen of Cisplatin, Cytarabine and Dexamethasone: A Potential Salvage Regimen for Relapsed or Refractory Diffuse Large B-Cell Lymphoma After Second-Line Treatment Failure
por: Hu, Junxia, et al.
Publicado: (2021)

No association between ECSIT germline mutations and hemophagocytic lymphohistiocytosis in natural killer/T-cell lymphoma
por: Ong, Shin Yeu, et al.
Publicado: (2020)

Fotemustine-based therapy in combination with rituximab as a first-line induction chemotherapy followed by WBRT for newly diagnosed primary central nervous system lymphoma: a prospective phase II trial
por: Wu, Jingjing, et al.
Publicado: (2022)

Prognostic significance of CD30 expression in nasal natural killer/T-cell lymphoma
por: Wang, Guan-Nan, et al.
Publicado: (2017)

The Effect of Chronic Rhinosinusitis on the Staging and Prognosis of Extranodal Natural Killer/T-Cell Lymphoma: A Single-Center Retrospective Analysis
por: Lei, Tingting, et al.
Publicado: (2022)

TIPE2 suppresses progression and tumorigenesis of esophageal carcinoma via inhibition of the Wnt/β-catenin pathway
por: Zhu, Linan, et al.
Publicado: (2018)

Case report of extranodal natural killer/T-cell lymphoma that induced secondary hemophagocytic syndrome-related histiocytic glomerulopathy
por: Xiao, Fei, et al.
Publicado: (2023)

Prognostic nomogram for overall survival in upper aerodigestive tract extranodal natural killer/T-cell lymphoma, nasal type, stages IE and IIE: A SEER-based study
por: Wang, Gangjian, et al.
Publicado: (2019)

Causes of mortality in cases with extra nodal natural killer/T-cell lymphoma, nasal type: A cohort study
por: Mei, Mei, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_7epdfke622ssj53m0932b7jp39